<?xml version="1.0" encoding="UTF-8"?>
<p id="p0615">Remdesivir is a nucleotide analogue prodrug that inhibits RNA-dependent RNA-polymerase, but it is not a Mpro protease inhibitor and only in a computational study it was suggested that may be an inhibitor of both proteins 
 <xref rid="b0765" ref-type="bibr">[153]</xref>. However, a clinical study about the compassionate use of remdesivir for patients with severe COVID-19 revealed a clinical improvement in 36 of 53 patients (68%), even though a placebo-controlled trial will be required 
 <xref rid="b0860" ref-type="bibr">[172]</xref>. In a second study, the remdesivir was not associated with statistically significant clinical benefits in adult patients with severe COVID-19, but a larger study will be required to confirm the data 
 <xref rid="b0865" ref-type="bibr">[173]</xref>.
</p>
